摘要
Abstract
Objective To study the efficacy of cinacalet tablet combined with calciriol capsule in the treatment of moderate to severe urimic hyperparathyroidism (UHPT) in patients with kidney disease.Methods A total of 82 patients with moderate to severe UHPT were randomly divided into control group (n =41 cases) and treatment group (n =41 cases).The control group received oral treatment of calcitriol with the initial dose of 0.25 μg if the patient can tolerate,the dose was adjusted to 0.5 μg,qd.The treatment group was given cinacalet(25 mg) on the basis of the control group.Both groups were treated for 3 months.The clinical efficacy,total parathyroid hormone (iPTH),alkaline phosphatase (ALP),phosphorus (P),calcium (Ca) and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of the treatment group and the control group respectively was 93.00％ (38 cases/41 cases) and 71.00％ (29 cases/41 cases),the difference was statistically significant (P ＜ 0.05).After treatment,there were significant differences between the treatment group and the control group in the iPTH [(218.61 ±19.77) vs (323.50 ±32.72)ng · L-1],ALP [(73.55 ±6.89) vs (118.79 ± 11.70) U· L-1],P [(1.32±0.12) vs (1.59 ±0.14)mmol · L-1],and Ca [(2.77 ±0.36) vs (2.33 ±0.28)mmol·L-1](P ＜ 0.05).The adverse drug reactions of the 2 groups were hypertension,myalgia,nausea and vomiting.The incidences of adverse drug reactions in the treatment group and the control group were 12.00％ (5 cases/41 cases) and 15.00％ (6 cases/41 cases),with no significant difference (P ＞ 0.05).Conclusion Cinacalet combined with calcitriol exerted high efficacy and safety profile in patients with moderate to severe UHPT caused by chronic dialysis.关键词
西那卡塞片/骨化三醇胶囊/慢性透析/尿液性甲状旁腺功能亢进Key words
cinacalet tablet/calcitriol capsule/chronic dialysis/urinary hyperparathyroidism分类
医药卫生
